ZRC 3278

Drug Profile

ZRC 3278

Alternative Names: AZD13721412; MMV674253; ZRC-3278

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; Medicines for Malaria Venture
  • Developer Zydus Cadila
  • Class Antimalarials; Small molecules
  • Mechanism of Action Vacuolar proton-translocating ATPase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 22 Jun 2017 Preclinical trials in Malaria in India before June 2017 (Zydus Cadila pipeline, June 2017)
  • 27 Sep 2016 Zydus Cadila and Medicines for Malaria Venture collaborate on the development of MMV 674253 for the treatment of malaria
  • 27 Sep 2016 Early research in Malaria in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top